Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB598 |
Synonyms | |
Therapy Description |
AB598 is an inhibitory monoclonal antibody against ENTPD1 (CD39), which blocks ATPase activity, leading to increased extracellular ATP and potential activation of the tumor microenvironment and inhibition of tumor growth (PMID: 38797955). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB598 | AB 598|AB-598 | CD39 Antibody 5 | AB598 is an inhibitory monoclonal antibody against ENTPD1 (CD39), which blocks ATPase activity, leading to increased extracellular ATP and potential activation of the tumor microenvironment and inhibition of tumor growth (PMID: 38797955). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |